MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

Home・Stock List・Cronos Group Inc

Cronos Group Inc

Open

SectorHealthcare

2.51 0.4

Buy Sell

Overview

Share price change

24h

Current

Min

2.48

Max

2.55

Key metrics
By Trading Economics
Income	-26M 2.4M
Sales	55M 91M
P/E Sector Avg	23.909 57.05
Profit margin	2.67
Employees	610
EBITDA	-75M -45M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+17.21% upside

Dividends
By Dow Jones
Next Earnings	7 May 2026

Market Stats
By TradingEconomics
Market Cap	-72M 938M
Previous open	2.11
Previous close	2.51

News Sentiment

By Acuity

100%

330 / 349 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

1.84 / N/A Support & Resistance

Cronos Group Inc Chart

Past performance is not a reliable indicator of future results.

Related News

31 Mar 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Nike, RH, NCino

31 Mar 2026, 22:35 UTC

Earnings

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 Apr 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 Mar 2026, 23:50 UTC

Acquisitions, Mergers, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 Mar 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 Mar 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 Mar 2026, 23:21 UTC

Earnings

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 Mar 2026, 23:14 UTC

Market Talk

Earnings

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 Mar 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 Mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss Widens >000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 Mar 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 Mar 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 Mar 2026, 21:35 UTC

Earnings

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 Mar 2026, 21:35 UTC

Earnings

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 Mar 2026, 21:35 UTC

Earnings

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 Mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 Mar 2026, 21:33 UTC

Earnings

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 Mar 2026, 21:32 UTC

Earnings

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 Mar 2026, 21:28 UTC

Earnings

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 Mar 2026, 21:26 UTC

Earnings

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 Mar 2026, 21:25 UTC

Earnings

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 Mar 2026, 21:24 UTC

Market Talk

Earnings

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 Mar 2026, 21:22 UTC

Earnings

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 Mar 2026, 21:22 UTC

Earnings

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 Mar 2026, 21:21 UTC

Earnings

Nike's Digital Channel Still Too Promotional, CFO Says

31 Mar 2026, 21:20 UTC

Earnings

Nike CEO: Converse Remains Important to Portfolio

Peer Comparison

Price change

Cronos Group Inc Forecast

Price Target

By TipRanks

17.21% upside

12 Months Forecast

Average 2.86 USD 17.21%

High 3.235 USD

Low 2.3 USD

Based on 3 Wall Street analysts offering 12 month price targets forCronos Group Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Cronos Group Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.84 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

330 / 349 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Cronos Group Inc

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.